16 January 2026

Genus plc ("Genus" or the "Group")

Half Year Trading Update - Ahead of expectations

Genus (LSE: GNS), a leading global animal genetics company, publishes the following unaudited trading update for the six months ended 31 December 2025 ("H1 FY26").

Genus performed strongly in H1 FY26 and the Board expects to report first half Group adjusted profit before tax (excluding the BCA milestone payment¹ referenced below) of approximately £50m in actual currency, which is ahead of our expectations. Including the BCA milestone payment, first half Group adjusted profit before tax is expected to be approximately £55.6m in actual currency.

Following the Group's AGM trading update in November 2025, PIC trading continued to be strong and ABS traded as expected. The Board now expects Group FY26 adjusted profit before tax (excluding the BCA milestone payment¹) to be moderately above the top-end of current market expectations².

On 4 September 2025, Genus announced the accelerated formation of its porcine joint venture in China³. The Group is pleased to confirm that formation of the joint venture received regulatory approval from SASAC⁴ in December 2025, which has also triggered the final $7.5m (c. £5.6m) milestone payment from BCA to Genus. Genus now expects formation of the Chinese porcine joint venture and receipt of the milestone cash payment in its fiscal third quarter.

Genus will announce its interim results for the six month period from 1 July 2025 to 31 December 2025 on 26 February 2026.

For further information please contact:

Genus plc      Tel: +44 (0)1256 345 970

Jorgen Kokke, Chief Executive Officer

Andy Russell, Chief Financial Officer

Anand Date, Investor Relations & Sustainability Director

Burson Buchanan    Tel: +44 (0)207 466 5000

Charles Ryland; Mark Court; Toto Berger; Jamie Hooper

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to animal breeding and genetic improvement by applying biotechnology and sells added value products for livestock farming and food producers. Its technology is applicable across livestock species and is currently commercialised by Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and breeding animals with superior genetics to those animals currently in farms. Genus's customers' animals produce offspring with greater production efficiency, and quality, and use these to supply the global dairy and meat supply chains.

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global supply chain, technical service and sales and distribution network. The PRRS⁵ Resistant Pig is a market leading innovation in gene editing which Genus is looking to commercialise in the porcine industry once further regulatory approvals are obtained.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in over twenty-five countries on six continents, with research laboratories located in Madison, Wisconsin, USA.

Footnotes

¹ Group adjusted profit before tax excludes the PRP-related milestone payment from BCA triggered by receipt of regulatory approval from SASAC⁴ and the financial impact from the planned formation of the Group's porcine joint venture in China

² The company compiled consensus estimate range for Group FY26 actual currency adjusted profit before tax is £82.7m to £85.0m with an average midpoint of £83.6m, and is based upon 9 analyst estimates

³ Accelerated Chinese porcine joint venture formation

⁴ China's State-owned Assets Supervision and Administration Commission of the State Council ("SASAC")

⁵ PRRS (Porcine Reproductive and Respiratory Syndrome) Resistant Pig ("PRP")